RPL17 and neoplasm: Similarly, FX-1 impaired the impact of anti-PD-1 mAb on OT-I CD8+ T cell proliferation in the lymph node (Fig. 6, C and D) but minimally affected OT-I CD8+ T cells at the tumor site (Fig. S4 I).